Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc (PRGO), a global pharmaceutical company incorporated in Ireland, filed this Current Report on Form 8-K on May 11, 2021. The filing announces the release of earnings results for the first quarter ended April 3, 2021. The detailed financial data is contained in the attached press release (Exhibit 99.1), which is not included in the text of this filing.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references the existence of GAAP and non-GAAP financial measures but does not list the actual figures.
Material Changes and Adjustments
The Company utilizes non-GAAP measures to exclude items affecting comparability. For the quarter ended April 3, 2021, adjustments included:
- Amortization expense related to acquired intangible assets.
- Acquisition and integration-related charges and contingent consideration adjustments.
- (Gain) loss on divestitures.
- Unusual litigation and restructuring charges.
- Non-GAAP tax adjustments and RX transitional business costs.
- Foreign currency translation movements.
- Net sales from specific acquisitions: Dr. Fresh, Ranir, and Eastern European Brands.
Comparisons to prior periods (March 28, 2020, and March 30, 2019) also exclude divested businesses such as the animal health business, Canoderm, Rosemont Pharmaceuticals, and infant foods product lines.
Guidance, Outlook, and Risks
Management uses adjusted financial measures for planning, forecasting, and determining compensation. The filing emphasizes that non-GAAP measures should be considered in conjunction with, not in lieu of, GAAP financial statements. No specific forward-looking guidance, risk factors, or unusual items beyond the listed adjustments are detailed in this text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and EPS figures.
- Verify the reconciliation between GAAP and non-GAAP measures to understand the impact of excluded items.
- Assess the impact of foreign currency translation on reported growth.
- Confirm the status of ongoing litigation and restructuring charges mentioned in the adjustments.
- Check for updates on the integration of recent acquisitions (Dr. Fresh, Ranir, Eastern European Brands).